Johnson & Johnson to acquire Ollin Biosciences for $2.2bn to expand ophthalmology pipeline

Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, adding the late-stage ophthalmology candidate OLN324 to its pipeline.

The transaction also includes the potential for approximately $1.125 billion in additional regulatory and commercial milestone payments.

Ollin is a clinical-stage biotechnology company developing treatments for serious retinal diseases.

Its lead asset, OLN324, is an investigational bispecific antibody designed to target vascular endothelial growth factor and angiopoietin-2, two pathways involved in retinal vascular disease.

The therapy is being developed for conditions including wet age-related macular degeneration and diabetic macular edema.

Johnson & Johnson said these diseases collectively affect more than 40 million people worldwide and represent major causes of vision loss.

OLN324 uses a smaller protein format described as a minibody and has been designed with high Ang2 potency.

The company said the approach could support stronger control of retinal fluid and potentially allow longer intervals between treatments.

Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, said the clinical data generated so far suggest OLN324 could provide more sustained disease control.

He added that the treatment could potentially reduce retinal fluid more effectively while decreasing the frequency of treatment.

Alongside the proposed acquisition, Johnson & Johnson will enter into a separate development funding agreement with Blackstone Life Sciences.

Blackstone will provide a total of $750 million over several years to fully fund the Phase III development of OLN324.

In return, Blackstone will be eligible for certain regulatory and sales milestone payments as well as single-digit royalties.

The funding arrangement is contingent on completion of Johnson & Johnson’s acquisition of Ollin.

Johnson & Johnson expects the acquisition to close before the end of 2026, subject to regulatory approvals and customary closing conditions.

The company said the transaction will strengthen its ophthalmology pipeline and broader strategy to preserve, restore and improve vision.

Johnson & Johnson plans to use its development, regulatory and commercial capabilities to advance OLN324 through late-stage development.

The accounting treatment for the transaction is expected to be announced on or before closing.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy